This paper is only available as a PDF. To read, Please Download here.
Abstract
Once-daily mometasone furoate nasal spray (MFNS) is a new intranasal glucocorticoid
for the treatment of seasonal allergic rhinitis and perennial rhinitis, and for the
prophylaxis of seasonal allergic rhinitis. This paper reviews key findings from the
clinical development program for MFNS, comprising more than 20 clinical trials with
more than 6000 patients worldwide. MFNS exhibits strong anti-inflammatory activity
in vitro and in vivo, and has a rapid onset of action, affording clinically significant
symptom relief in 28% of patients within 12 hours of the first dose. Once-daily MFNS
is at least as effective as other intranasal glucocorticoids, including twice-daily
beclomethasone dipropionate and once-daily fluticasone propionate and budesonide.
MFNS is well tolerated and has no detectable effect on the hypothalamic-pituitary-adrenal
axis, even at up to 20 times the recommended daily dose. MFNS does not cause atrophy
of the nasal mucosa; in fact, prolonged treatment tends to restore the nasal mucosa
to a more normal phenotype. The once-daily dosing schedule of MFNS may improve patient
compliance, while its high margin of systemic safety and rapid onset of action may
enhance patient and physician acceptance
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical TherapeuticsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Glucocorticoids and rhinitis.Allergy. 1993; 4: 476-490
- Today's approach to controlling allergic rhinitis.J Respir Dis. 1992; 13 (Suppl 6): S30-S39
- Allergic rhinitis.NEJM. 1991; 325: 860-869
- Glucocorticoids in the management of upper respiratory allergy: The emerging role of steroid nasal sprays.Otolaryngol Head Neck Surg. 1992; 107: 855-860
- Glucocorticoids in otolaryngology: Nasal aerosols.Otolaryngol Head Neck Surg. 1989; 100: 636-637
- A clinical investigation of the efficacy and safety of mometasone furoate ointment 0.1% versus betamethasone valerate ointment 0.1% in the treatment of psoriasis.Curr Ther Res. 1988; 44: 790-801
- Comparison of the effect of mometasone furoate ointment 0.1%, and hydrocortisone ointment 1.0%, on adrenocortical function in psoriasis patients.Today's Ther Trends. 1988; 5: 25-34
- Mometasone furoate ointment and cream 0.1 percent in treatment of psoriasis: Comparison with ointment and cream formulations of fluocinolone acetonide 0.025 percent and triamcinolone acetonide 0.1 percent.Curtis. 1988; 42: 480-485
- Cytokine inhibition by a novel steroid mometasone furoate.Immunopharmacol Immunotoxicol. 1991; 13: 251-261
- Effects of mometasone furoate and other glucocorticoids on cytokine production from cultured peripheral blood CD4+ T cells.J Allergy Clin Immunol. 1996; 97 (Abstract): 288
- The effect of mometasone furoate on early and late phase inflammation in patients with seasonal allergic rhinitis (SAR).Ann Allergy Asthma Immunol. 1997; 78 (Abstract): 129
- Dose ranging study of the activity and tolerance of mometasone furoate in seasonal allergic rhinitis.Allergy. 1996; 50 (Abstract): 191-192
- Onset of action of mometasone furoate (Nasonex) nasal spray in seasonal allergic rhinitis.J Allergy Clin Immunol. 1997; 99 (and the C93-184 Study Group) (Abstract): S441
- Once daily mometasone furoate aqueous nasal spray (Nasonex) in seasonal allergic rhinitis: An active- and placebo-controlled study.Allergy. 1996; 51: 569-576
- A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray.J Allergy Clin Immunol. 1996; 98: 724-731
- Prophylactic use of once-daily mometasone furoate (Nasonex) aqueous nasal spray in patients with seasonal allergic rhinitis.J Allergy Clin Immunol. 1997; 99 (and the 193-133 Study Group) (Abstract): S440
- Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for perenial allergic rhinitis patients.Ann Allergy Asthma Immunol. 1996; 77: 153-160
- Comparison of once-daily treatment with mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis.J Allergy Clin Immunol. 1997; 99 (Abstract): S441
Nasonex®. Schering-Plough Inc., Kenilworth, New Jersey. Product Information.
- Lack of systemic activity with intranasal mometasone furoate.J Allergy Clin Immunol. 1996; 97 (Abstract): 198
- Lack of HPA axis suppression following 36 days of intranasal momentasone furoate.Ann Allergy Asthma Immunol. 1997; 78 (Abstract): 154
Data on file, Schering-Plough Research Institute, Schering-Plough Inc., Kenilworth, NJ, 1996.
- Histological and immunocytochemical assessment by nasal biopsy of mometasone furoate nasal spray in perennial rhinitis.J Allergy Clin Immunol. 1997; 99 (Abstract): S498
- How often is medication taken as prescribed? A novel technique.JAMA. 1989; 261: 3273-3277
Article info
Identification
Copyright
© 1997 Published by Elsevier Inc.
